PMID- 15749931
OWN - NLM
STAT- MEDLINE
DCOM- 20050823
LR  - 20061115
IS  - 1066-5099 (Print)
IS  - 1066-5099 (Linking)
VI  - 23
IP  - 3
DP  - 2005 Mar
TI  - A new strategy for treatment of malignant tumor: intra-bone marrow-bone marrow 
      transplantation plus CD4- donor lymphocyte infusion.
PG  - 365-70
AB  - Donor lymphocyte infusion (DLI) is clinically used for the treatment of malignant 
      tumors. We have found recently that intra-bone marrow-bone marrow transplantation 
      (IBM-BMT) can be used to treat various autoimmune diseases, even when radiation 
      doses are reduced. In addition, recently we have found that IBM-BMT can prevent 
      not only graft failure but also graft-versus-host disease (GvHD). Based on these 
      findings, we attempted to prevent and treat the progression of a tumor (Meth-A 
      cell line: BALB/c-derived fibrosarcoma) by DLI plus IBM-BMT. When the tumors had 
      grown to approximately 10 x 10 mm, the tumor-bearing BALB/c (H-2(d)) mice were 
      irradiated with 5 Gy, and whole spleen cells from C57BL/6J (B6) (H-2(b)) mice (as 
      DLI) were then intravenously injected into the BALB/c mice. Simultaneously, bone 
      marrow cells (BMCs) from B6 mice were injected directly into the bone marrow 
      cavity of the BALB/c mice (IBM-BMT). The tumors decreased in size, but the mice 
      died of GvHD. However, when CD4(+) T-cell-depleted spleen cells were used for 
      DLI, the recipients showed only mild GvHD and survived longer, due to the slow 
      growth of the tumor. In contrast, when CD8(+) T-cell-depleted spleen cells were 
      used for DLI, the recipients showed more severe GvHD than those injected with 
      whole spleen cells. These results suggest that IBM-BMT plus DLI (the depletion or 
      reduction of a certain cell population like CD4(+) T cells) could be helpful to 
      suppress both GvHD and tumor growth.
FAU - Suzuki, Yasuhiro
AU  - Suzuki Y
AD  - First Department of Pathology, Kansai Medical University, Moriguchi City, Osaka 
      570-8506, Japan.
FAU - Adachi, Yasushi
AU  - Adachi Y
FAU - Minamino, Keizo
AU  - Minamino K
FAU - Zhang, Yuming
AU  - Zhang Y
FAU - Iwasaki, Masayoshi
AU  - Iwasaki M
FAU - Nakano, Keiji
AU  - Nakano K
FAU - Koike, Yasushi
AU  - Koike Y
FAU - Ikehara, Susumu
AU  - Ikehara S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Stem Cells
JT  - Stem cells (Dayton, Ohio)
JID - 9304532
SB  - IM
MH  - Animals
MH  - Body Weight
MH  - Bone Marrow Transplantation/*methods
MH  - CD4-Positive T-Lymphocytes/immunology/*transplantation
MH  - Fibrosarcoma/mortality/pathology/*therapy
MH  - Graft vs Host Disease/immunology
MH  - Graft vs Tumor Effect/immunology
MH  - Lymphocyte Depletion
MH  - Lymphocyte Transfusion/*methods
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Sarcoma, Experimental/mortality/pathology/therapy
MH  - Spleen/cytology/immunology
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2005/03/08 09:00
MHDA- 2005/08/24 09:00
CRDT- 2005/03/08 09:00
PHST- 2005/03/08 09:00 [pubmed]
PHST- 2005/08/24 09:00 [medline]
PHST- 2005/03/08 09:00 [entrez]
AID - 23/3/365 [pii]
AID - 10.1634/stemcells.2004-0258 [doi]
PST - ppublish
SO  - Stem Cells. 2005 Mar;23(3):365-70. doi: 10.1634/stemcells.2004-0258.